-
WestGene Biopharma’s EB Virus-Targeting mRNA Vaccine WGc-043 Clears for Clinical Trials in China
•
WestGene Biopharma Co., Ltd., a biotechnology company based in Chengdu, has received approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) to proceed with clinical trials for its candidate drug, WGc-043. This marks a significant milestone as WGc-043 is the world’s first mRNA therapeutic…
-
WestGene Biopharma’s Groundbreaking mRNA Vaccine for EB Virus Tumors Gets FDA Green Light
•
WestGene Biopharma Co., Ltd., a biopharmaceutical company based in Chengdu, has announced that its drug candidate WGc-043 has been approved for clinical trials by the US Food and Drug Administration (FDA). WGc-043 is recognized as the world’s first clinically approved mRNA therapeutic vaccine targeting Epstein-Barr (EB) virus-related tumors. The vaccine…
-
Westgene Biopharma Secures RMB 150M Series A Financing for mRNA Drug Development
•
Westgene Biopharma, an mRNA drug developer based in Chengdu, reportedly raised RMB 150 million (USD 21.49 million) in a Series A financing round, led by Chengdu Wenjiang Emerging Industry Venture Capital Fund Partnership Limited, Tigermed Consulting, Yingke PE, Huaxin Asset Management, and Sichuan Mansaisi Pharma. Company Background and PipelineFounded in…
